Dennis M. Brown
Known title: Chief Scientific OfficerCIK: 0001569520
Associated companies
Transaction History
| HURA | ▼ Sell | Other | 363 | $0 | 1/5/2023 | View on chart |
| HURA | ▲ Buy | Grant | 240,087 | $0 | 8/1/2022 | View on chart |
| HURA | ▼ Sell | Other | 363 | $0 | 1/5/2023 | View on chart |
| HURA | ▲ Buy | Grant | 240,087 | $0 | 8/1/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HURA Secures U.S. Patent for DOR Antagonist Delivery
TuHURA Biosciences has been granted a U.S. patent covering the administration of DOR antagonists. The approval protects the company’s delivery technology and could support future drug development or licensing deals. The patent may strengthen HURA’s intellectual property portfolio and provide a competitive edge in the field of opioid receptor research.
HURA Secures U.S. Patent for DOR Antagonist Delivery. TuHURA Biosciences has been granted a U.S. patent covering the administration of DOR antagonists. The approval protects the company’s delivery technology and could support future drug development or licensing deals. The patent may strengthen HURA’s intellectual property portfolio and provide a competitive edge in the field of opioid receptor research.